Dianthus Therapeutics (STU:87E) Common Stock: €0.05 Mil (As of Mar. 2026)


STU:87E Dianthus Therapeutics Inc STU:87E
22 GF Score
Price €82.00
GF Value €2.53
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Common Stock?

Dianthus Therapeutics STU:87E 22 Common Stock is €0.05 Mil as of Mar. 2026. GuruFocus rates STU:87E with a GF Score™ of 22/100 and a GF Value™ of €2.53 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Dianthus Therapeutics's quarterly common stock stayed the same from Sep. 2025 (€0.04 Mil) to Dec. 2025 (€0.04 Mil) but then increased from Dec. 2025 (€0.04 Mil) to Mar. 2026 (€0.05 Mil).

Dianthus Therapeutics's annual common stock increased from Dec. 2023 (€0.01 Mil) to Dec. 2024 (€0.03 Mil) and increased from Dec. 2024 (€0.03 Mil) to Dec. 2025 (€0.04 Mil).

Dianthus Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Dianthus Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dianthus Therapeutics Common Stock Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
0.00 0.00 0.01 0.03 0.04

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.04 0.04 0.05
STU:87E
22GF Score
Dianthus Therapeutics Inc STU:87E
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dianthus Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €0.05 Mil mean?
Dianthus Therapeutics (STU:87E) has a Common Stock of €0.05 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Dianthus Therapeutics and its competitors.
Is Dianthus Therapeutics' Common Stock too high?
Dianthus Therapeutics' current Common Stock is €0.05 Mil. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Common Stock compare to CAI and TNGX?
Dianthus Therapeutics' Common Stock of €0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Dianthus Therapeutics and its competitors. Dianthus Therapeutics's current Common Stock is €0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (STU:87E) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.53, compared to a current price of €82.00 — trading 3141.1% above its estimated fair value. The current Common Stock is €0.05 Mil. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Dianthus Therapeutics (STU:87E), the current Common Stock is €0.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dianthus Therapeutics (STU:87E) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of €82.00 is trading 3141.1% above its estimated GF Value™ of €2.53. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:87E:

  • Common Stock: €0.05 Mil
  • GF Value™: €2.53 vs. price of €82.00 (3141.1% above fair value)
  • GF Score™: 22/100 with 7 warning signs

No single metric tells the full story. See the STU:87E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Other Exchanges DNTH:USA
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for STU:87E

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€82.00
Price
€2.53
GF Value